At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 152 enrolled
Drug / intervention
iloprost +1 moredrug
Likely dose
Iloprost orally (specific dose not stated)AI-extracted
Key inclusion· 7
- ✓Current or former smoker with ≥20 pack-year history and ≥6 months tobacco abstinence
- ✓Mild atypia or worse on sputum cytology within past 12 months
- ✓Bronchial biopsy with mild or worse dysplasia within the past 12 months
- ✓Age ≥18 years
Key exclusion· 9
- ✕Clinically apparent bleeding diathesis
- ✕Ventricular tachycardia or multifocal premature ventricular contractions
- ✕Pneumonia or acute bronchitis within past 2 weeks
- ✕Hypoxemia with saturation <90% on supplemental oxygen
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Chemoprevention Study of Iloprost Versus Placebo in Patients at High Risk for Lung Cancer
In Brief
A Phase 2 clinical trial evaluating iloprost and placebo for Lung Cancer and Precancerous Condition. Completed, enrolled 152 participants across 6 sites.
Detailed Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Precancerous Condition
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2001
First PostedJun 2004
Primary CompletionJan 2009
TodayJul 2026
First PostedJun 11, 2004
Enrollment StartNov 1, 2001
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 22.1 years ago
Interventions
iloprostdrug
Given orally
placeboother
Given orally